A new approach to control immune responses in the body
A modular cell therapy platform for controlling immunological tolerance
This study is working on a new type of cell therapy that helps your immune system learn to ignore harmless substances, which could lead to better treatments for conditions like autoimmune diseases, cancer, and organ transplants, all while reducing side effects from current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10899598 on NIH RePORTER |
What this research studies
This research focuses on developing a modular cell therapy platform aimed at controlling immunological tolerance, which is crucial for preventing unwanted immune reactions against non-harmful substances. By leveraging advancements in T cell biology and synthetic biology, the project seeks to create therapies that can specifically target and regulate immune responses without broadly suppressing the immune system. This could lead to more effective treatments for autoimmune diseases, cancer, and organ transplantation, minimizing adverse effects associated with current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases, those undergoing organ transplantation, or patients with certain cancers.
Not a fit: Patients with conditions that do not involve immune system dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with safer and more effective treatments for autoimmune diseases and improve outcomes in organ transplantation.
How similar studies have performed: Previous research has shown promise in developing targeted immunotherapies, indicating potential for success in this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Reticker-Flynn, Nathan Edward — Stanford University
- Study coordinator: Reticker-Flynn, Nathan Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.